Showing 4141-4150 of 9407 results for "".
- Fever and Abdominal Purpura Linked to IgAV Recurrence in Adultshttps://practicaldermatology.com/news/fever-and-abdominal-purpura-linked-to-igav-recurrence-in-adults/2485592/Systemic corticosteroids and post-bacterial etiology may protect against recurrence or relapse in adult immunoglobulin A vasculitis (IgAV), a new study suggests. Investigators for the retrospective cohort study
- Analysis: ChatGPT and DeepSeek Largely Align With Psoriasis Treatment Guidelineshttps://practicaldermatology.com/news/analysis-chatgpt-and-deepseek-largely-align-with-psoriasis-treatment-guidelines/2485578/Large language models (LLMs) ChatGPT and DeepSeek generally adhere to established psoriasis treatment guidelines, but some performance gaps remain. Investigators publishing in the Journal of Drugs in Dermatology exp
- Icotrokinra Maintains Psoriasis Responses With Continuous Treatmenthttps://practicaldermatology.com/news/icotrokinra-maintains-psoriasis-responses-with-continuous-treatment/2485554/Continuous treatment with icotrokinra resulted in durable psoriasis control through one year, while treatment withdrawal was associated with rapid loss of response, according to “Maintenance of Response With Icotrokinra for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results From the Ph
- Deuruxolitinib Produces Progressive Hair Regrowth in Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-produces-progressive-hair-regrowth-in-severe-alopecia-areata/2485553/Deuruxolitinib produced progressive and clinically meaningful scalp hair regrowth in patients with severe alopecia areata, according to “Deuruxolitinib Improves Scalp Hair Regrowth Over Time in Patients With Severe Alopecia Areata,” a poster by Natasha A. Mesinkovska, MD, PhD, et al presented as
- Risankizumab Maintains Efficacy and Safety in Pediatric Psoriasis Through 52 Weekshttps://practicaldermatology.com/news/risankizumab-maintains-efficacy-and-safety-in-pediatric-psoriasis-through-52-weeks/2485552/Risankizumab maintained or improved clinical response through one year in pediatric patients with moderate-to-severe plaque psoriasis, according to “Efficacy and Safety of Risankizumab in Pediatric Patients With Psoriasis: Results Through 52 Weeks,” a poster by Nina Magnolo, MD, et al presented a
- Povorcitinib Improves Lesion Burden and Pain in Hidradenitis Suppurativahttps://practicaldermatology.com/news/povorcitinib-improves-lesion-burden-and-pain-in-hidradenitis-suppurativa/2485551/Oral povorcitinib produced early and sustained improvements in lesion burden and pain in patients with moderate-to-severe hidradenitis suppurativa (HS), according to “Effect of Povorcitinib on Hidradenitis Suppurativa Lesions Through 24 Weeks in STOP-HS Trials,” a poster by Jennifer L. Hsiao, MD,
- ORKA-001 Phase 1 Data Support Potential Once-Yearly IL-23 Dosinghttps://practicaldermatology.com/news/orka-001-phase-1-data-support-potential-once-yearly-il-23-dosing/2485550/A half-life–extended IL-23p19 monoclonal antibody demonstrated sustained pharmacokinetics and favorable tolerability that may support once-yearly dosing in plaque psoriasis, according to “Phase 1 Clinical Data of ORKA-001, a Novel Half-Life–Extended IL-23p19 Monoclonal Antibody,” a poster by Jame
- 23-Gene Expression Profiling Accurately Classifies Pediatric Melanocytic Lesionshttps://practicaldermatology.com/news/23-gene-expression-profiling-accurately-classifies-pediatric-melanocytic-lesions/2485549/A 23-gene expression profiling assay accurately distinguished benign nevi from melanoma in pediatric patients, according to “23-GEP Accurately Distinguishes Between Melanocytic Nevi and Melanoma in Pediatric Melanocytic Neoplasms,” a poster by Drazen Jukic, MD, et al presented as part of the “Bes
- Dupilumab Produces Early and Sustained Improvements in CSU Activityhttps://practicaldermatology.com/news/dupilumab-produces-early-and-sustained-improvements-in-csu-activity/2485548/Dupilumab produced early and sustained reductions in urticaria activity in patients with chronic spontaneous urticaria (CSU), according to “Dupilumab Provides Early and Sustained Improvement in Urticaria Activity in Patients With Chronic Spontaneous Urticaria,” a poster by Jonathan A. Bernstein,
- Arcutis Reports Positive Phase 2 Data for Infant Atopic Dermatitis Programhttps://practicaldermatology.com/news/arcutis-reports-positive-phase-2-data-for-infant-atopic-dermatitis-program/2485557/Arcutis Biotherapeutics reported positive topline results from the phase 2 INTEGUMENT-INFANT trial evaluating investigational ZORYVE® (roflumilast) cream 0.05% in infants aged 3 months to younger than 24 months with mild to moderate atopic dermatitis (AD).